Bottom line
PRHSX vs HRTS: the short answer
PRHSX (T. Rowe Price Health Sciences Fund, Inc.) and HRTS (Tema Heart & Health ETF) share a meaningful slice of their top holdings — about 54% by weight.
But PRHSX is far broader, holding 279 positions to 45 for HRTS, so beyond the top names it adds exposure HRTS doesn't have.
HRTS is cheaper at 0.75% vs 0.83% — a difference of $8.00 a year per $10,000 invested.
Over one year, HRTS returned +23.6% vs +17.7% for PRHSX.
Updated Nov 19, 2026
PRHSX vs HRTS side by side
| PRHSX | HRTS | |
|---|---|---|
| Type | Mutual fund | ETF |
| Fund family | T. Rowe Price | Innovator |
| Category | Health Care Sector | Health Care Sector |
| Expense ratio | 0.83% | 0.75% |
| Annual cost per $10k | $83 | $75 |
| 10-yr cost on $10k (prospectus) | $1,025 | $1,168 |
| Max front load | — | None |
| 12b-1 fee | — | 0% |
| 1-yr return | +17.7% | +23.6% |
| 5-yr return (annualized) | +4.2% | — |
| 10-yr return (annualized) | +9.1% | — |
| Best quarter | +23.5% | +15.8% |
| Worst quarter | −15.8% | −12.4% |
| Net assets (fund) | $11.9B | $51.9M |
| Number of holdings | 279 | 45 |
| Portfolio turnover | 62% | 4% |
| Returns as of | Dec 31, 2025 | Dec 31, 2025 |
Source: SEC Form N-PORT and fund prospectuses
Year-by-year returns
| Year | PRHSX | HRTS | Difference |
|---|---|---|---|
| 2025 | +17.7% | +23.6% | −5.9% |
| 2024 | +1.8% | +3.6% | −1.8% |
Source: Fund prospectus bar charts
Holdings overlap
12 of PRHSX's top 25 holdings also appear in HRTS's top 25.
| Holding | PRHSX | HRTS |
|---|---|---|
| Eli Lilly & Co | 14.28% | 11.52% |
| Johnson & Johnson | 6.63% | 3.59% |
| Unitedhealth Group Inc | 5.99% | 5.24% |
| Abbvie Inc | 5.10% | 2.40% |
| Merck & Co. Inc. | 4.01% | 4.27% |
| Gilead Sciences Inc | 2.82% | 3.43% |
| Thermo Fisher Scientific Inc | 2.52% | 3.97% |
| Vertex Pharmaceuticals Inc | 2.28% | 2.93% |
| Bristol-myers Squibb Co | 2.11% | 2.09% |
| Abbott Laboratories | 1.89% | 2.61% |
| Amgen Inc | 1.82% | 1.91% |
| Danaher Corp | 1.43% | 2.66% |
Source: SEC Form N-PORT
PRHSX top 10
- Eli Lilly & Co — 14.28%
- Johnson & Johnson — 6.63%
- Unitedhealth Group Inc — 5.99%
- Abbvie Inc — 5.10%
- Merck & Co. Inc. — 4.01%
- Gilead Sciences Inc — 2.82%
- Thermo Fisher Scientific Inc — 2.52%
- Vertex Pharmaceuticals Inc — 2.28%
- Bristol-myers Squibb Co — 2.11%
- Abbott Laboratories — 1.89%
HRTS top 10
- Eli Lilly & Co — 11.52%
- UnitedHealth Group Inc — 5.24%
- Novo Nordisk A/S — 5.24%
- Roche Holding AG — 4.50%
- Merck & Co Inc — 4.27%
- AstraZeneca PLC — 4.00%
- Thermo Fisher Scientific Inc — 3.97%
- Johnson & Johnson — 3.59%
- Gilead Sciences Inc — 3.43%
- Novartis AG — 3.38%
FAQ
What is the difference between PRHSX and HRTS?
Which is cheaper, PRHSX or HRTS?
Should I own both PRHSX and HRTS?
Educational comparison based on public filings; not investment advice. Past performance does not guarantee future results.